The Diagnostic Performance of Neurofilament Light Chain in CSF and Blood for Alzheimer's Disease, Frontotemporal Dementia, and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis

Overview

Journal Alzheimers Dement (Amst)

Date 2020 Jan 8

PMID 31909174

Citations 76

Authors

Lauren M Forgrave

Matthew Ma

John R Best

Mari L DeMarco

Affiliations

Soon will be listed here.

Abstract

Introduction: A systematic review and meta-analysis was performed regarding the diagnostic performance of neurofilament light chain (NfL) in CSF and blood.

Methods: A database search was conducted for NfL biomarker studies in the context of Alzheimer's disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) compared with controls (i.e., cognitively unimpaired, mild cognitive impairment, or disease mimics).

Results: In groups with a sufficient number of studies, the performance of NfL in blood and CSF was similar. Compared with disease mimics, we observed that CSF NfL had strong discriminatory power for ALS, modest discriminatory power for FTD, and no discriminatory power for AD. NfL provided the greatest separation between ALS and cognitively unimpaired controls in both the blood and CSF, followed by FTD (CSF and blood), then AD (blood and CSF).

Discussion: Comparable performance of CSF and blood NfL in many groups demonstrates the promise of NfL as a noninvasive biomarker of neurodegeneration; however, its utility in clinically meaningful scenarios requires greater scrutiny. Toward clinical implementation, a more comprehensive understanding of NfL concentrations in disease subtypes with overlapping phenotypes and at defined stages of disease, and the development of a harmonization program, are warranted.

Citing Articles

Plasma Biomarkers in the Distinction of Alzheimer's Disease and Frontotemporal Dementia.

Gomez-Tortosa E, Aguero-Rabes P, Ruiz-Gonzalez A, Wagner-Reguero S, Tellez R, Mahillo I Int J Mol Sci. 2025; 26(3).

PMID: 39940998 PMC: 11818795. DOI: 10.3390/ijms26031231.

Predicting conversion in cognitively normal and mild cognitive impairment individuals with machine learning: Is the CSF status still relevant?.

Russo M, Nardini D, Melchiorre S, Ciprietti C, Polito G, Punzi M Alzheimers Dement. 2025; 21(2):e14398.

PMID: 39887916 PMC: 11848327. DOI: 10.1002/alz.14398.

Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review.

Squitti R, Fiorenza A, Martinelli A, Brembati V, Crescenti D, Rongioletti M Int J Mol Sci. 2025; 26(1.

PMID: 39795920 PMC: 11719531. DOI: 10.3390/ijms26010061.

Heritability of Alzheimer's disease plasma biomarkers: A nuclear twin family design.

Rousset R, den Braber A, Verberk I, Boonkamp L, Wilson D, Ligthart L Alzheimers Dement. 2024; 21(1):e14269.

PMID: 39588748 PMC: 11775461. DOI: 10.1002/alz.14269.

Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.

Liampas I, Kyriakoulopoulou P, Karakoida V, Kavvoura P, Sgantzos M, Bogdanos D Int J Mol Sci. 2024; 25(21).

PMID: 39519389 PMC: 11546606. DOI: 10.3390/ijms252111838.

References

Gaetani L, Hoglund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P . A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018; 10(1):8. PMC: 6389166. DOI: 10.1186/s13195-018-0339-1. View

Benatar M, Wuu J, Andersen P, Lombardi V, Malaspina A . Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018; 84(1):130-139. PMC: 11348288. DOI: 10.1002/ana.25276. View

Pijnenburg Y, Verwey N, van der Flier W, Scheltens P, Teunissen C . Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2016; 1(4):505-12. PMC: 4879490. DOI: 10.1016/j.dadm.2015.11.001. View

Wilke C, Rattay T, Hengel H, Zimmermann M, Brockmann K, Schols L . Serum neurofilament light chain is increased in hereditary spastic paraplegias. Ann Clin Transl Neurol. 2018; 5(7):876-882. PMC: 6043776. DOI: 10.1002/acn3.583. View

van Eijk J, van Everbroeck B, Abdo W, Kremer B, Verbeek M . CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J Alzheimers Dis. 2010; 21(2):569-76. DOI: 10.3233/JAD-2010-090649. View

Mattsson N, Andreasson U, Zetterberg H, Blennow K . Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017; 74(5):557-566. PMC: 5822204. DOI: 10.1001/jamaneurol.2016.6117. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Feldman H, Frisoni G . A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016; 87(5):539-47. PMC: 4970664. DOI: 10.1212/WNL.0000000000002923. View

Sjogren M, Wallin A . Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity. Mech Ageing Dev. 2001; 122(16):1923-35. DOI: 10.1016/s0047-6374(01)00303-7. View

Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppo P . The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther. 2018; 10(1):3. PMC: 5784714. DOI: 10.1186/s13195-017-0331-1. View

10.

Rosengren L, Karlsson J, Sjogren M, Blennow K, Wallin A . Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999; 52(5):1090-3. DOI: 10.1212/wnl.52.5.1090. View

11.

Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen P . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2015; 87(1):12-20. DOI: 10.1136/jnnp-2015-311387. View

12.

Kester M, Scheffer P, Koel-Simmelink M, Twaalfhoven H, Verwey N, Veerhuis R . Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging. 2011; 33(8):1591-8. DOI: 10.1016/j.neurobiolaging.2011.05.013. View

13.

Reijn T, Abdo W, Schelhaas H, Verbeek M . CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009; 256(4):615-9. DOI: 10.1007/s00415-009-0131-z. View

14.

Verde F, Steinacker P, Weishaupt J, Kassubek J, Oeckl P, Halbgebauer S . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018; 90(2):157-164. DOI: 10.1136/jnnp-2018-318704. View

15.

Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P . Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):71. PMC: 6064615. DOI: 10.1186/s13195-018-0404-9. View

16.

Pereira J, Westman E, Hansson O . Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiol Aging. 2017; 58:14-29. DOI: 10.1016/j.neurobiolaging.2017.06.002. View

17.

Niikado M, Chrem-Mendez P, Itzcovich T, Barbieri-Kennedy M, Calandri I, Martinetto H . Evaluation of Cerebrospinal Fluid Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic. J Gerontol A Biol Sci Med Sci. 2018; 74(4):442-445. DOI: 10.1093/gerona/gly179. View

18.

Ashton N, Leuzy A, Lim Y, Troakes C, Hortobagyi T, Hoglund K . Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019; 7(1):5. PMC: 6327431. DOI: 10.1186/s40478-018-0649-3. View

19.

Wellington H, Paterson R, Suarez-Gonzalez A, Poole T, Frost C, Sjobom U . CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Ann Clin Transl Neurol. 2018; 5(2):162-171. PMC: 5817822. DOI: 10.1002/acn3.518. View

20.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View